All In Biotech

Drug Trial Radar · NCT04630067

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

A Phase Ia/b Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Single Ascending Doses of AZD3427 in Healthy Volunteers and Multiple Ascending Doses of AZD3427 in Patients With Heart Failure (HFrEF and HF With EF ≥ 41%)

Last checked: Nov 19, 2026Latest source record: Oct 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Nov 17, 2020

Primary completion

Sep 14, 2022

Study completion Sep 14, 2022

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This first-time-in-human (FTIH) study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single doses of AZD3427 in healthy volunteers and multiple doses of AZD3427 in patients with heart failure (HF).

Conditions

  • Heart Failure

Interventions

  • AZD3427Drug

    Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

  • PlaceboDrug

    Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse Events and Serious Adverse EventsTime frame: Part A: Day 1 until Day 50 or Early termination visit (E/T); Part B: Day 1 until Day 78 or E/T

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Glendale, California

  • Research Site

    Daytona Beach, Florida

  • Research Site

    Doral, Florida

  • Research Site

    Hallandale, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Owensboro, Kentucky

  • Research Site

    Brooklyn, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.